Compare POLA & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | VRAX |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 1.7M |
| IPO Year | 2016 | 2021 |
| Metric | POLA | VRAX |
|---|---|---|
| Price | $1.63 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 904.4K | 157.1K |
| Earning Date | 05-15-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,801,141.00 | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $1.31 | $0.17 |
| 52 Week High | $5.70 | $1.34 |
| Indicator | POLA | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 37.27 |
| Support Level | $1.52 | N/A |
| Resistance Level | $1.77 | $0.25 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 19.30 | 2.59 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.